Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Mikus

Showing results (71-80 of 86) with videos related to

Pageof 9
Sort By:
Arzneimittel-Forschung|September 14, 1999
Experimental studies on guanosine 3',5'-cyclic monophosphate levels and airway responsiveness of the novel phosphodiesterase type 5 inhibitor SR 265579 in guinea-pigsZ Kapui, P Schaeffer, E G Mikus, et al.
Infection|October 17, 2002
Treatment of life-threatening multiresistant staphylococcal and enterococcal infections in patients with end-stage renal failure with quinupristin/dalfopristin: preliminary reportV Schwenger, E Mündlein, E E Dagrosa, et al.
Schmerz (Berlin, Germany)|July 5, 2017
[Erratum to: Management of chronic pain using extended release tilidine : Quality of life and implication of comedication on tilidine metabolism]C Wolfert, M Merbach, G Stammler, et al.
Clinical Pharmacology and Therapeutics|November 24, 2001
Ritonavir increases loperamide plasma concentrations without evidence for P-glycoprotein involvementY Tayrouz, B Ganssmann, R Ding, et al.
International Journal of Clinical Pharmacology and Therapeutics|August 30, 2007
Reduction in non-glomerular renal clearance of the caffeine metabolite 1-methylxanthine by probenecidJ Rengelshausen, C Göggelmann, J Burhenne, et al.
Schmerz (Berlin, Germany)|June 10, 2017
[Management of chronic pain using extended release tilidine : Quality of life and implication of comedication on tilidine metabolism]C Wolfert, M Merbach, G Stammler, et al.
Arzneimittel-Forschung|January 20, 1999
Experimental studies on the antitussive properties of the new xanthine derivative 1H-purine-2,6-dione, 3,7-dihydro-3-methyl-7[(5-methyl-1,2,4-oxadiazol-3-yl) methyl]. 3rd communication: examinations on opioid mechanisms and physical drug dependenceZ Kapui, E G Mikus, J Bence, et al.
Pharmacogenetics|March 25, 1998
Assessment of the predictive power of genotypes for the in-vivo catalytic function of CYP2D6 in a German populationE U Griese, U M Zanger, U Brudermanns, et al.
European Journal of Clinical Pharmacology|January 1, 1996
Impact of quinidine on plasma and cerebrospinal fluid concentrations of codeine and morphine after codeine intakeS H Sindrup, U Hofmann, J Asmussen, et al.
International Journal of Clinical Pharmacology and Therapeutics|April 10, 2008
Calcium balance during calcitriol and paricalcitol administration in healthy humansV Hafner, C Rutsch, R Ding, et al.
Pageof 9

Showing results (71-80 of 86) with videos related to

Sort By:
Pageof 9
Arzneimittel-Forschung|September 14, 1999
Experimental studies on guanosine 3',5'-cyclic monophosphate levels and airway responsiveness of the novel phosphodiesterase type 5 inhibitor SR 265579 in guinea-pigsZ Kapui, P Schaeffer, E G Mikus, et al.
Infection|October 17, 2002
Treatment of life-threatening multiresistant staphylococcal and enterococcal infections in patients with end-stage renal failure with quinupristin/dalfopristin: preliminary reportV Schwenger, E Mündlein, E E Dagrosa, et al.
Schmerz (Berlin, Germany)|July 5, 2017
[Erratum to: Management of chronic pain using extended release tilidine : Quality of life and implication of comedication on tilidine metabolism]C Wolfert, M Merbach, G Stammler, et al.
Clinical Pharmacology and Therapeutics|November 24, 2001
Ritonavir increases loperamide plasma concentrations without evidence for P-glycoprotein involvementY Tayrouz, B Ganssmann, R Ding, et al.
International Journal of Clinical Pharmacology and Therapeutics|August 30, 2007
Reduction in non-glomerular renal clearance of the caffeine metabolite 1-methylxanthine by probenecidJ Rengelshausen, C Göggelmann, J Burhenne, et al.
Schmerz (Berlin, Germany)|June 10, 2017
[Management of chronic pain using extended release tilidine : Quality of life and implication of comedication on tilidine metabolism]C Wolfert, M Merbach, G Stammler, et al.
Arzneimittel-Forschung|January 20, 1999
Experimental studies on the antitussive properties of the new xanthine derivative 1H-purine-2,6-dione, 3,7-dihydro-3-methyl-7[(5-methyl-1,2,4-oxadiazol-3-yl) methyl]. 3rd communication: examinations on opioid mechanisms and physical drug dependenceZ Kapui, E G Mikus, J Bence, et al.
Pharmacogenetics|March 25, 1998
Assessment of the predictive power of genotypes for the in-vivo catalytic function of CYP2D6 in a German populationE U Griese, U M Zanger, U Brudermanns, et al.
European Journal of Clinical Pharmacology|January 1, 1996
Impact of quinidine on plasma and cerebrospinal fluid concentrations of codeine and morphine after codeine intakeS H Sindrup, U Hofmann, J Asmussen, et al.
International Journal of Clinical Pharmacology and Therapeutics|April 10, 2008
Calcium balance during calcitriol and paricalcitol administration in healthy humansV Hafner, C Rutsch, R Ding, et al.
Pageof 9